Quick Notes: Divestiture and Collaboration — Sept. 6, 2024

This edition of Quick Notes features announcements of UCB’s divestiture of its Chinese neurology and allergy business and collaborations between Bayer and NextRNA, Flagship Pioneering and Pfizer, and Adcendo and Multitude Therapeutics.
Source: Drug Industry Daily